Cambridge Healthtech Institute’s 6th Annual

Characterization of Biotherapeutics

January 20-21, 2020

Part of the Analytics & Impurities pipeline


The popular 6th Annual Characterization of Biotherapeutics conference will bring together will bring together leading scientists from biopharmaceutical industry, academia and government to discuss case studies, new technologies, assay on analytical development and characterization of mAbs, ADCs, bispecifics, and other novel protein formats, biosimilar. Some of the hot topics for discussion this year will include regulatory expectations and developability of new product formats, cell and gene therapy products, biosimilars, high-throughput analytics, multi attribute methods, glycosylation/post-translational modifications and biophysical assays and more.

We invite you to submit a proposal, present a poster and attend to join with colleagues in this discussion of the key challenges and solutions improving predication, screening and characterization of new biologics.


Coverage will include, but is not limited to:

  • Developability and Analytical Characterization and New Assay:
    • Antibody drug conjugates (ADCs), bispecifics, multi-specifics, fusion proteins fusion proteins oligos, new protein formats and new viral therapeutics
    • Cell and gene therapy products
    • Biosimilars and analytical comparability
    • Characterization of conjugation
  • Structure, Function and Stability Relationship:
    • Higher order structure (HOS) characterization in biologics
    • Glycosylation/post-translational modifications
    • Protein conformation
    • Determining CQA and acceptance criteria
    • Pharmacology and in vivo characterization
    • Biophysical characterization and property based molecular design
  • Analytics:
    • Mass spectroscopy
    • New tools for sequence variance analysis and multi-attribute analysis
    • High-throughput assays, automation, in line assays and miniaturized assay
    • Characterization of process impurities, product variants, post translational modifications
    • Biodistribution and in vivo fate of biologics: Case studies on correlation between in vitro and in vivo findings


* The program is subject to change without notice, due to unforeseen reason.

2020 Conferences & Training Seminars